Eris Lifesciences Ltd ERIS
NSE · India · Health Technology
INR 1,190.80-1.10 (-0.09%)
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Eris Lifesciences Ltd (NSE:ERIS) reports robust revenue growth driven by domestic formulations, while addressing challenges in cardiac segments and margin pressures.
Five-Year Agreement Extends Commercial Reach Across India, LATAM, Russia, Australia and New Zealand Fort Pierce, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR), a consumer brands company specializing in skin care and hair growth, and SanPellegrino Cosmetics Private Limited (“SCPL”), a New Delhi-based specialty pharma and dermatology licensing company, today announced the execution of a revised multi-territory licensing agreement covering Photocil and Hair Enzyme Booste
Eris Lifesciences Ltd (NSE:ERIS) reports robust revenue and EBITDA growth, driven by a significant increase in insulin market share and strategic product launches.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.